GENELUX Corp
GNLXNext catalyst
olvimulogene nanivacirepvec
Platinum-resistant Ovarian Cancer
Get an email about GNLX's next catalysts
Track GENELUX (GNLX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (Phase 2 readout).See the timeline
4 upcoming, 1 past
Olvi-Vec Phase 2 Est. Readout
Estimated primary completion for Olvi-Vec trial (NCT07136285) in SCLC, Extensive Stage. Topline data typically follows completion by weeks to months.
Sourceolvimulogene nanivacirepvec Phase 3 Est. Readout
Estimated primary completion for olvimulogene nanivacirepvec trial (NCT05281471) in Platinum-resistant Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourcePlatinum chemotherapy: carboplatin or cisplatin Phase 2 Est. Readout
Primary completion for Platinum chemotherapy: carboplatin or cisplatin trial (NCT06463665) in Advanced Non-squamous Non-small-cell Lung Cancer
SourceOlvimulogene nanivacirepvec Phase 2 Est. Readout (VIRO-25)
Estimated primary completion for Olvimulogene nanivacirepvec trial (NCT06463665) in Advanced Non-squamous Non-small-cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.
Websiteolvimulogene nanivacirepvec
Platinum-resistant Ovarian Cancer
Platinum chemotherapy: carboplatin (preferred) or cisplatin
Platinum-resistant Ovarian Cancer
Olvi-Vec
Ovarian Cancer
platinum (cisplatin or carboplatin)
SCLC, Extensive Stage
Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Advanced Non-squamous Non-small-cell Lung Cancer
GL-ONC1
Peritoneal Carcinomatosis
Platinum-doublet with or without bevacizumab
Ovarian Cancer
Platinum chemotherapy: carboplatin or cisplatin
Advanced Non-squamous Non-small-cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
olvimulogene nanivacirepvec | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
Platinum chemotherapy: carboplatin (preferred) or cisplatin | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
Olvi-Vec | Phase 2 | Ovarian Cancer | - | - |
platinum (cisplatin or carboplatin) | Phase 2 | SCLC, Extensive Stage | - | - |
Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC | Phase 2 | Advanced Non-squamous Non-small-cell Lung Cancer | - | - |
GL-ONC1 | Phase 2 | Peritoneal Carcinomatosis | - | - |
Platinum-doublet with or without bevacizumab | Phase 2 | Ovarian Cancer | - | - |
Platinum chemotherapy: carboplatin or cisplatin | Phase 2 | Advanced Non-squamous Non-small-cell Lung Cancer | - | - |
Frequently asked questions
What is in GENELUX Corp's drug pipeline?→
CatalystAlert tracks 8 drug candidates in GENELUX Corp's (GNLX) pipeline across Phase 3, Phase 2. Its lead program is olvimulogene nanivacirepvec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GENELUX Corp's next FDA catalyst?→
GENELUX Corp's (GNLX) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GNLX biotech catalysts?→
Add GNLX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GENELUX Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.